Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Enterprise Value (2022 - 2026)

Axsome Therapeutics' Enterprise Value history spans 6 years, with the latest figure at -$305.1 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 1.4% to -$305.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$305.1 million, a 1.4% decrease, with the full-year FY2025 number at -$322.9 million, down 2.4% from a year prior.
  • Enterprise Value hit -$305.1 million in Q1 2026 for Axsome Therapeutics, up from -$322.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for AXSM hit a ceiling of -$73.4 million in Q2 2022 and a floor of -$437.1 million in Q2 2023.
  • Historically, Enterprise Value has averaged -$289.4 million across 5 years, with a median of -$315.4 million in 2024.
  • Biggest five-year swings in Enterprise Value: plummeted 495.57% in 2023 and later rose 27.79% in 2024.
  • Tracing AXSM's Enterprise Value over 5 years: stood at -$200.8 million in 2022, then crashed by 92.29% to -$386.2 million in 2023, then rose by 18.34% to -$315.4 million in 2024, then decreased by 2.4% to -$322.9 million in 2025, then increased by 5.52% to -$305.1 million in 2026.
  • Business Quant data shows Enterprise Value for AXSM at -$305.1 million in Q1 2026, -$322.9 million in Q4 2025, and -$325.3 million in Q3 2025.